{"slideshow_credits": null, "snippet": "The results, though not conclusive, provide the first evidence that targeting a protein known as PCSK9 could reduce cardiovascular risks for millions of patients.", "abstract": "Researchers report at European Society of Cardiology's annual meeting that experimental cholesterol-lowering drug from Sanofi and Regeneron Pharmaceuticals cut roughly in half number of heart attacks and strokes in clinical trial.", "section_name": "Business Day", "print_page": "4", "document_type": "article", "byline": {"person": [], "organization": "REUTERS", "original": "By REUTERS", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/09/01/business/international/cholesterol-drug-halves-heart-attack-and-stroke-in-early-test.html", "lead_paragraph": "The results, though not conclusive, provide the first evidence that targeting a protein known as PCSK9 could reduce cardiovascular risks for millions of patients.", "headline": {"main": "Cholesterol Drug Halves Heart Attack and Stroke in Early Test", "print_headline": "Drug Halves Heart Attack and Stroke in Early Test"}, "_id": "5403a38738f0d80e250f417e", "word_count": "365", "multimedia": [], "pub_date": "2014-09-01T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Cholesterol", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "N", "rank": "2"}, {"value": "Sanofi SA", "name": "organizations", "is_major": "Y", "rank": "3"}, {"value": "Regeneron Pharmaceuticals Inc", "name": "organizations", "is_major": "Y", "rank": "4"}, {"value": "Research", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "Stroke", "name": "subject", "is_major": "Y", "rank": "6"}, {"value": "Heart", "name": "subject", "is_major": "Y", "rank": "7"}], "blog": [], "subsection_name": "International Business", "type_of_material": "News"}